• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesTry Devex Pro
    • News
    • Ebola

    Ebola vaccine given the go-ahead in 5 African countries

    DRC, Burundi, Ghana, Zambia, and Guinea have become the first to license the vaccine, which has been effective in 97.5% of cases, preliminary results show.

    By Emma Smith // 18 February 2020
    A scene at an Ebola vaccination campaign in Butembo, the Democratic Republic of the Congo. Photo by: MONUSCO / Force / CC BY-SA

    BARCELONA — Five African countries have become the first to license a highly effective Ebola vaccine, meaning it can now be administered without being subject to clinical trial or research protocols.

    Regulatory bodies in the Democratic Republic of the Congo, Burundi, Ghana, Zambia, and Guinea all approved the vaccine in the past week. Several other countries are expected to do so in the coming weeks.

    When the current Ebola outbreak began in DRC, a vaccine had been developed but not yet approved. The World Health Organization accelerated certification and access to it with unprecedented speed in an effort to contain the outbreak, which has already claimed more than 2,200 lives.

    Ebola in DRC: NGOs organize to coordinate community engagement work

    NGOs responding to the Ebola emergency in the Democratic Republic of the Congo have formed a consortium to help better involve communities.

    “It’s not a treatment, it’s a vaccination but it does have an effect on the course of the disease even if you're already exposed, explained Margaret Harris, a spokesperson for WHO.

    Just three months ago, the agency declared that the vaccine met quality, safety, and efficiency standards. This prequalification made it possible for African countries to start their own regulatory processes, which they did in tandem, Harris said. Once a country has licensed the vaccine, they are essentially free to decide how to use it.

    The vaccine was one of five treatments approved in June 2018 by an ethics committee in DRC under a research protocol, also known as “compassionate use” or “expanded access.” Under these protocols, the drug could be administered as long as consent was obtained from the patient and monitoring protocols were followed. The vaccine has so far been issued to more than 290,000 people in DRC as well as health and frontline workers in Uganda, South Sudan, Rwanda, and Burundi.

    Preliminary results indicate that the rVSV-ZEBOV-GP vaccine, an injectable manufactured by Merck, or MSD as it is known outside the United States and Canada, has been effective in 97.5% of cases and could reduce the chances of death in those already infected. 

    “We know that even if somebody has already been exposed, already infected, if we vaccinate them, the course of disease is far less severe [and] ... the survival rate is very, very high,” Harris said.

    In DRC, the vaccine was initially delivered by WHO employees who were brought in mainly from Guinea, which is considered to be a world expert when it comes to the Ebola vaccine, Harris said — a randomized trial of the vaccine was first rolled out there during the 2015 West Africa outbreak.

    The vaccination technology was then transferred to local teams who received training and played an important role in getting communities on board. The DRC Ministry of Public Health is now increasingly running these teams.

    The vaccine has been a “huge game-changer,” Harris said. The downside is that people might now believe Ebola can be easily beaten. But the vaccine alone cannot eradicate Ebola and building community trust is still critical, Harris cautioned, referencing what has become one of the big challenges of the Ebola response.

    It’s important to listen to communities and understand how they interpret the situation, to ensure that people who have been exposed to the disease feel safe in identifying themselves, she said.

    • Global Health
    • WHO
    • Guinea
    • Zambia
    • Congo, The Democratic Republic of
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).

    About the author

    • Emma Smith

      Emma Smith@emmasmith_bcn

      For four years, Emma Smith covered careers and recruitment, among other topics, for Devex. She now freelances for Devex and has a special interest in mental health, immigration, and sexual and reproductive health. She holds a degree in journalism from Glasgow Caledonian University and a master’s in media and international conflict.

    Search for articles

    Related Stories

    Global HealthOutbreak of the Sudan strain of Ebola declared in Uganda

    Outbreak of the Sudan strain of Ebola declared in Uganda

    Global healthInside the infamous ‘Tunnel 12’: The source of Rwanda’s Marburg outbreak

    Inside the infamous ‘Tunnel 12’: The source of Rwanda’s Marburg outbreak

    Devex CheckUpDevex CheckUp: How Trump’s first 100 days fractured global health

    Devex CheckUp: How Trump’s first 100 days fractured global health

    Devex NewswireDevex Newswire: Which awards are spared — and which aren’t — at USAID

    Devex Newswire: Which awards are spared — and which aren’t — at USAID

    Most Read

    • 1
      How low-emissions livestock are transforming dairy farming in Africa
    • 2
      Opinion: Mobile credit, savings, and insurance can drive financial health
    • 3
      Opinion: India’s bold leadership in turning the tide for TB
    • 4
      The UN's changing of the guard
    • 5
      USAID's humanitarian bureau is under pressure and overstretched
    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2025 Devex|User Agreement|Privacy Statement
    We use cookies to help improve your user experience. By using our site, you agree to the terms of our Privacy Policy.